Shire Plc (SHPG) announced that the FDA has approved its Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. It is the first prescription eye drop indicated for the treatment of both signs and symptoms of this condition. U.S. market launch should commence in Q3.